

STEM CELLS

Copy of e-mail Notification

STEM CELLS Co-Published by AlphaMed Press and Wiley-Blackwell

Dear Author,

YOUR PAGE PROOFS ARE AVAILABLE IN PDF FORMAT; please refer to this URL address

<http://115.111.50.156/jw/retrieval.aspx?pwd=997bcec6ca26>

Login: your e-mail address

Password: 997bcec6ca26

The site contains 1 file. You will need to have Adobe Acrobat Reader software to read these files. This is free software and is available for user downloading at <http://www.adobe.com/products/acrobat/readstep.html>.

This file contains:

Adobe Acrobat Users - NOTES tool sheet

Reprint Order Information

A copy of your page proofs for your article

Please read the page proofs carefully and:

- 1) indicate changes or corrections in the margin of the page proofs;
- 2) answer all queries
- 3) proofread any tables and equations carefully;
- 4) check that any special characters have translated correctly.

Special Notes:

We strongly encourage you to return your corrections electronically to STEMprod@wiley.com. If you would prefer to fax your corrections, please send them to 1-201-748-6182.

Please return your corrections within 48 hours to avoid a delay in the publication of your article. Thank you for your cooperation.

Return to:

fax: 201-748-6182

Email: STEMprod@wiley.com

Softproofing for advanced Adobe Acrobat Users – NOTES tool

NOTE: ADOBE READER FROM THE INTERNET DOES NOT CONTAIN THE NOTES TOOL USED IN THIS PROCEDURE.

Acrobat annotation tools can be very useful for indicating changes to the PDF proof of your article. By using Acrobat annotation tools, a full digital pathway can be maintained for your page proofs.

The NOTES annotation tool can be used with either Adobe Acrobat 6.0 or Adobe Acrobat 7.0. Other annotation tools are also available in Acrobat 6.0, but this instruction sheet will concentrate on how to use the NOTES tool. Acrobat Reader, the free Internet download software from Adobe, DOES NOT contain the NOTES tool. In order to softproof using the NOTES tool you must have the full software suite Adobe Acrobat Exchange 6.0 or Adobe Acrobat 7.0 installed on your computer.

Steps for Softproofing using Adobe Acrobat NOTES tool:

1. Open the PDF page proof of your article using either Adobe Acrobat Exchange 6.0 or Adobe Acrobat 7.0. Proof your article on-screen or print a copy for markup of changes.
2. Go to Edit/Preferences/Commenting (in Acrobat 6.0) or Edit/Preferences/Commenting (in Acrobat 7.0) check “Always use login name for author name” option. Also, set the font size at 9 or 10 point.
3. When you have decided on the corrections to your article, select the NOTES tool from the Acrobat toolbox (Acrobat 6.0) and click to display note text to be changed, or Comments/Add Note (in Acrobat 7.0).
4. Enter your corrections into the NOTES text box window. Be sure to clearly indicate where the correction is to be placed and what text it will effect. If necessary to avoid confusion, you can use your TEXT SELECTION tool to copy the text to be corrected and paste it into the NOTES text box window. At this point, you can type the corrections directly into the NOTES text box window. **DO NOT correct the text by typing directly on the PDF page.**
5. Go through your entire article using the NOTES tool as described in Step 4.
6. When you have completed the corrections to your article, go to Document/Export Comments (in Acrobat 6.0) or Comments/Export Comments (in Acrobat 7.0). Save your NOTES file to a place on your harddrive where you can easily locate it. **Name your NOTES file with the article number assigned to your article in the original softproofing e-mail message.**
7. **When closing your article PDF be sure NOT to save changes to original file.**
8. To make changes to a NOTES file you have exported, simply re-open the original PDF proof file, go to Document/Import Comments and import the NOTES file you saved. Make changes and reexport NOTES file keeping the same file name.
9. When complete, attach your NOTES file to a reply e-mail message. Be sure to include your name, the date, and the title of the journal your article will be printed in.



Additional reprint purchases

Should you wish to purchase additional copies of your article, please click on the link and follow the instructions provided:

<https://caesar.sheridan.com/reprints/redirect.php?pub=10089&acro=STEM>

Corresponding authors are invited to inform their co-authors of the reprint options available.

Please note that regardless of the form in which they are acquired, reprints should not be resold, nor further disseminated in electronic form, nor deployed in part or in whole in any marketing, promotional or educational contexts without authorization from Wiley. Permissions requests should be directed to mail to: permissionsus@wiley.com

For information about 'Pay-Per-View and Article Select' click on the following link: wileyonlinelibrary.com/aboutus/ppv-articleselect.html

return proof with your signature below

Approved by _____ Date _____

STEM CELLS[®]

TRANSLATIONAL AND CLINICAL RESEARCH

Concise Review: Bone Marrow for the Treatment of Spinal Cord Injury: Mechanisms and Clinical Applications

AQ1 KARINA T. WRIGHT,^{a,b,c} WAGIH EL MASRI,^{a,b,c} AHEED OSMAN,^{a,b,c} JOY CHOWDHURY,^{a,b,c} WILLIAM E. B. JOHNSON^{a,b,c}

AQ2 ^aSpinal Studies and Midlands Centre for Spinal Injuries, RJA Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom; ^bInstitute of Science and Technology in Medicine, Keele University, Keele, Staffordshire, United Kingdom; ^cSchool of Life and Health Sciences, Aston University, Birmingham, United Kingdom

Key Words. Adult human bone marrow • Spinal cord injury • Cell transplantation • Clinical translations and clinical trials

ABSTRACT

Transplantation of bone marrow stem cells into spinal cord lesions enhances axonal regeneration and promotes functional recovery in animal studies. There are two types of adult bone marrow stem cell; hematopoietic stem cells (HSCs), and mesenchymal stem cells (MSCs). The mechanisms by which HSCs and MSCs might promote spinal cord repair following transplantation have been extensively investigated. The objective of this review is to discuss these mechanisms; we briefly consider the contro-

versial topic of HSC and MSC transdifferentiation into central nervous system cells but focus on the neurotrophic, tissue sparing, and reparative action of MSC grafts in the context of the spinal cord injury (SCI) milieu. We then discuss some of the specific issues related to the translation of HSC and MSC therapies for patients with SCI and present a comprehensive critique of the current bone marrow cell clinical trials for the treatment of SCI to date. *STEM CELLS 2010;000:000-000*

Disclosure of potential conflicts of interest is found at the end of this article.

SPINAL CORD INJURY AND THE INTRINSIC RESPONSE

When axons in the central nervous system (CNS) are damaged they mount a poor regenerative response due to a combination of inflammation, resulting in extensive neuronal and glial cell death and glial cell activation and hypertrophy, which contributes to the formation of the glial scar. These intrinsic responses to tissue injury both contribute to an environment that is inhibitory to axonal regrowth [1].

Inflammation

Following spinal cord injury (SCI), the blood-brain barrier is disrupted and an influx of inflammatory cells occurs, which is facilitated by their expression of matrix metalloproteinases (MMPs) [2]. MMPs, other proteolytic and oxidative enzymes, and proinflammatory cytokines that are produced by infiltrating neutrophils and macrophages, along with resident microglia, induce a reactive process of secondary cell death in the tissue that surrounds the original injury site [2-4]. This secondary damage continues in the days and weeks following SCI, which may lead to an increase in cavitation and cyst formation at the center of the lesion, exacerbating neurological dysfunction [5].

Some evidence suggests that inflammation may be a beneficial response to SCI. For example, macrophages phagocytose the myelin debris present in the injured spinal cord, which is

known to inhibit axonal regeneration [6, 7], and increase in the number of macrophages in a CNS injury can promote nerve regrowth [8]. In addition, macrophages may also release protective cytokines such as basic fibroblast growth factor, nerve growth factor (NGF), and neurotrophin 3, which promote neuronal regeneration and tissue repair [9].

Glial Scarring

Glial scarring involves astrocytes, which are activated in an effort to restore the blood-brain barrier, and oligodendrocytes. The extracellular matrix produced by these scar-associated cells contains a number of molecules that inhibit axonal regrowth [10] of which chondroitin-sulfated (CS) proteoglycans (PG) are the major inhibitory molecules synthesized by reactive astrocytes. CSPGs consist of a protein core to which glycosaminoglycan (GAG) side chains are attached. Much of the evidence suggests that the inhibitory activity of CSPGs is derived from their CS GAG side chains, as treatments with chondroitinase ABC (which cleaves these chains) reduces CSPG inhibition to neurites in vitro [11] and regenerating axons in vivo [12].

Other inhibitory molecules present within the glial scar include myelin-associated proteins, such as myelin-associated glycoprotein (MAG), Nogo-A, and oligodendrocyte-myelin glycoprotein (OMgp) [6, 7]. MAG is a potent inhibitor of neurite outgrowth when used as a culture substrate [6], which is expressed by oligodendrocytes and Schwann cells. MAG signals through the Nogo-66 receptor complex (NgR), but

Author contributions: K.T.W., W.E.M., and W.E.B.J.: conception and design and manuscript writing; W.E.B.J.: financial support; K.T.W.: provision of study material, collection and assembly of data and data analysis and interpretation; K.T.W., W.E.M., A.O., J.C., and W.E.B.J.: final approval of manuscript.

AQ11 Correspondence: Karina T. Wright, Ph.D., ISTM, Keele University based at the RJA Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom. Telephone: 44-1691-404699; Fax: • • •; e-mail: karina.wright@rjah.nhs.uk Received July 22, 2010; accepted for publication November 10, 2010; first published online in *STEM CELLS EXPRESS* Month 00, 2010; available online without subscription through the open access option. © AlphaMed Press 1066-5099/2009/\$30.00/0 doi: 10.1002/stem.570

STEM CELLS 2010;000:000-000 www.StemCells.com

there are several other neuronal receptors, which interact with the NgR complex and MAG to influence downstream signaling [13]. Nogo-A and OMgp are also derived from oligodendrocytes and act as inhibitors of axonal growth [14]. A number of different regions of Nogo-A contribute to its inhibitory activity, and it is probable that these different regions bind to not only the NgR complex but also to unidentified Nogo-A receptors in the CNS [14]. In contrast, OMgp appears to be dependent on the NgR complex, as cleavage of NgR renders axons insensitive to OMgp-induced growth inhibition [15].

HOW MIGHT BONE MARROW STEM CELL TRANSPLANTATION HELP HEAL THE INJURED SPINAL CORD?

There are two types of bone marrow stem cell, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which are known to differentiate into hematopoietic and mesenchymal cell lineages, respectively (supporting information Fig. 1). For clinical transplantation, HSCs and MSCs represent attractive cell sources as they can be easily and reproducibly isolated from bone marrow aspirates and reintroduced into patients as autografts. In animal models of SCI, their transplantation has promoted remyelination [16–18], axonal sparing, and functional recovery [19–31]. Many studies have documented successful engraftment of HSCs and MSCs into the injured spinal cord [19–31].

HSC and MSC Isolation, Culture, and Characterization

HSCs are defined by their lifelong ability to reconstitute all of the hematopoietic lineages in transplanted hosts [32]. Although HSCs have been shown to proliferate in vivo, there are as yet no definitive in vitro assays to detect and expand purified HSCs, as HSCs in long-term culture form progenitor populations that differentiate along the hematopoietic lineages. Researchers have yet to find a single molecular marker that is exclusively expressed by HSCs. However, HSCs can be distinguished and isolated from mature blood cells by their lack of lineage-specific markers and presence of other cell surface antigens such as CD34 and CD133 [33]. CD34 has been used routinely to enrich freshly isolated hematopoietic cell populations, which include HSC, for clinical transplantation in patients [34]. MSCs are a population of cells that differentiate along various mesenchymal lineages, for example, to form osteoblasts, adipocytes, and chondrocytes [35]. These multipotent cells have received considerable interest as possible donor cells for cell transplantation therapies because MSCs can be isolated from bone marrow with relative ease. Adherent stromal cells (MSCs) will outgrow any fully differentiated and nonproliferating cells, which might also adhere to bone marrow mononuclear cell seeded-culture plates. Unlike HSCs, MSCs can be culture expanded to generate large numbers [36]. Similar to HSCs, a single molecular marker that is exclusively expressed by MSCs is yet to be found, although the International Society for Cellular Therapy has stated that MSCs must express CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14, CD11b, CD79a, or CD19, and HLA-DR surface molecules [37].

HSCs and MSCs As Replacements for Lost Glial Cells and Neurons

Some evidence has suggested that HSCs and MSCs may transdifferentiate along glial and neuronal pathways [23, 27,

38–41]. The topic of MSC neural transdifferentiation in particular has been extensively reviewed elsewhere [38–41]. In brief, many of these studies have reported that HSCs and MSCs have the ability to form cells of a glial and neuronal lineage in response to various types of genetic, chemical, and/or physiological induction. In most cases, the characterization of cell phenotype was limited to the detection of lineage-specific markers with no glial or neuronal cell function apparent, that is, myelin synthesis or electrophysiological activity. There is some controversy regarding the capacity of MSCs to transdifferentiate into neural cells in vitro and in vivo. The differentiation of stem cells toward a neuronal lineage in development is a complex and gradual progression. In contrast, in vitro studies have described neuronal differentiation in a matter of hours following the treatment of MSC with chemical agents (e.g., β mercaptoethanol, dimethyl sulfoxide, and butylated hydroxyanisole), which is highly questionable. Such chemically induced transdifferentiation of various cell types including primary rat fibroblasts, rat PC-12 cells (a cell line that is used to model neuronal differentiation), and MSCs has previously been tested [42]. On application of induction medium, all cell types altered morphologically and appeared to possess fine neurite-like extensions. However, time lapse analysis indicated that these structures were due to cellular shrinkage and not to neurite extension proper. These researchers went on to introduce various other known cell stressors, including detergents, sodium chloride, and extreme pH levels, which also produced a similar morphological change to give the appearance of neuronal differentiation. Cellular shrinkage could also explain the apparent increase in immunoreactivity of neuronal markers (e.g., β III tubulin) exhibited in these differentiation protocols, as immunolocalization in cells, which had retracted cell processes, would appear to be more intense than in spread cells, which had received no treatment [42]. Doubts were also raised regarding the interpretation of in vivo studies that have reported transdifferentiation of MSCs [43, 44], where it has been suggested that the supposed MSC differentiation into neuronal phenotypes were rather a result of fusion between donor MSCs and host neural cells, which lead to false immunopositive characterization [45]. However, some studies have demonstrated phenotypic functions in transplanted HSC and MSC, that is, nerve myelination and electrophysiological activity for evident glial and neuronal phenotypic function [27, 46–48]. Interestingly, neuronal induction of MSCs prior to their transplantation into SCI lesions was not necessary to promote axonal regeneration when induced and noninduced MSC grafts were directly compared [49]. In addition, the glial or neuronal differentiation of HSCs and MSCs prior to their transplantation into CNS injury sites was not necessary to promote the remyelination, axonal regeneration, and functional recovery noted by the majority of investigators in the field [16–31]. Therefore, there is a clear possibility that HSCs and MSCs may have beneficial effects that extend beyond their potential to differentiate in vitro to form replacement cells of a glial or neuronal lineage.

MSCs Can Modify the SCI Milieu to Support Axonal Regeneration

The precise mechanisms by which transplantation of HSCs and MSCs promote functional recovery after SCI is still unclear. HSCs secrete some neurotrophic growth factors, such as angiopoietin-1 and have been suggested to encourage vascularization [50] and hence encourage wound healing in SCI. However, the majority of data available describes how MSC grafts can influence the SCI milieu, and therefore, this review has focused on MSC mechanisms (supporting information

Fig. 2). There is increasing evidence that MSCs may be immunosuppressive [51–54]. These immunosuppressive properties may combine to reduce the acute inflammatory response to SCI and hence reduce cavity formation as well as decrease astrocyte and microglia/macrophage reactivity [26, 30, 55]. MSC transplantation has been shown not only to enhance tissue preservation after SCI but also to associate with a reduction in injury-induced sensitivity to mechanical stimuli in an experimental SCI model, which is functionally indicative of anti-inflammatory activity [55]. Overall, these findings indicate that MSC transplantation into SCI lesions attenuates acute inflammation and that this is beneficial to the recovery of function following SCI. However, SCI initiates an innate immune response that participates not only in secondary pathogenesis but also in wound healing [56], therefore further research into the use of MSC as modulators of the immune system is required.

Transplanted MSCs might bring about CNS functional recovery by modifying the SCI milieu directly. MSCs may promote axonal regeneration or encourage functional plasticity by establishing an environment, which supports axonal growth, for example, by abrogating the inhibitory influence of the glial scar. MSCs synthesize a number of neurotrophic cytokines that stimulate nerve growth, including brain-derived neurotrophic factor, NGF, and vascular endothelial growth factor (VEGF) [26, 57], and we, and others, have shown that MSC conditioned media (MSC CM) stimulates neurite outgrowth in vitro [26, 58]. However, we have also demonstrated that the stimulus of MSC CM was insufficient to promote nerve growth over inhibitory molecules that are present in the glial scar, that is, CSPGs, MAG, and Nogo-A [56]. An important interpretation of this finding is that the neurotrophic factors secreted by MSCs may have limited effect in the context of the SCI milieu.

It has been proposed that MSCs act as “guiding strands” for regenerating axons across the lesion site in the injured cord and along spinal cord tracts in vivo [20]. Transplanted MSCs were seen to form bundles that bridged the lesion, which were also populated with immature astrocytes and nerve fiber outgrowths [20]. In coculture experiments, we used time lapse microscopy to demonstrate that MSCs can act directly both to provide contact guidance and cellular bridges over nerve-inhibitory matrices [58]. Human MSCs express various cell adhesion molecules and receptors [57] that may function in MSC: neuronal interactions and hence axonal regeneration. These include *ninjurin 1* and *2*, *Netrin 4*, neuronal cell adhesion molecule [57], *Robo1*, and *Robo4*, which are all known to regulate neuronal cell migration and axon guidance in development [59]. Alternatively, MSCs might degrade nerve-inhibitory molecules present in the SCI milieu. Human MSCs express membrane type I matrix metalloproteinase and MMP2, which degrade CSPGs [60–62]. Another interesting possibility is that transplanted MSCs synthesize nerve-permissive matrix components within the lesion that may contribute to the decrease in cavitation noted in some studies [21, 22], for example, laminin, fibronectin, and collagen [22]. Evidence that MSCs provide a supportive environment for neurite elongation has been shown in vitro, where a feeder layer of MSC enhanced the development of neural networks from neurospheres isolated from fetal rat spinal cords [21].

A recent study has focused on the ability of MSCs to respond to the environmental stimuli in the injured spinal cord. MSCs that were administered with extracts from injured spinal cord tissue responded by increasing their synthesis of various cytokines, including IL-6, IL-7, and VEGF [63]. The biological significance of the elevated secretion of these cyto-

kines is difficult to interpret as each factor could play a functional role in wound repair as well as a detrimental role in secondary tissue damage. However, this study demonstrated that there was a dynamic relationship between the transplanted MSCs and the host SCI environment. Elucidating and manipulating these interactions will provide an extremely complex area for future scientific research.

THE TRANSLATION OF BONE MARROW CELL TRANSPLANTATION TO THE CLINIC

HSC and MSC Populations in Humans with SCI

A preliminary question for the application of autologous HSCs or MSCs for human SCI cell therapy is whether these cells are available in individuals who have been injured. Early work demonstrated marked and significant changes in the composition of iliac crest tissue in individuals with complete paralysis compared with non-SCI donors [64]. In the 12–25 weeks after SCI, trabecular bone volume decreases by 30%, whereas the volume of bone marrow adipose tissue increases. The loss of mechanical loading following SCI is suggested to be a crucial stimulus for bone resorption [65]. However, surgical and chemical denervation in animal models leads to bone loss in both loaded and unloaded bones [66], which suggests that denervation in itself can contribute to the skeletal pathology observed following SCI. It is intuitive that such changes in the bone marrow microenvironment will have an impact on cells resident within marrow, although there is little data on whether this does occur. HSC populations are affected by SCI, where a reduced presence of long-term colony-forming dendritic cells has been determined. This loss of hematopoietic potential may have a role to play in the depressed natural and adaptive immunity seen in patients with SCI [67]. For MSCs, one study has reported successfully isolating “fibroblast-like mesenchymal cells” in just 75% of bone marrow aspirates tested from patients with SCI [68], which may suggest that the MSC population is also affected. However, more recently, we have shown that MSCs were generated from all SCI donor bone marrow samples that we have examined and that these MSCs were little if at all different to those isolated from non-SCI donors [69]. Importantly, we also found that MSCs from SCI donors were able to promote nerve growth, at least in vitro [69]. These findings bode well for the future development of bone marrow cell therapies for the treatment of SCI.

Clinical Applications of Bone Marrow Cell: Cell Type and Number, Mode, and Time of Delivery

In practice, most clinical applications of bone marrow cells for the treatment of SCI have involved the use of whole mononuclear cells preparations (MCPs) [70–75] and two have used culture expanded MSCs [76, 77]. MCPs constitute hematopoietic cells of various stages of differentiation and endothelial cells as well HSCs and MSCs. No studies have directly compared the efficacy of these various bone marrow cell preparations in the clinic, although a direct comparison was recently made between human MCPs and culture expanded MSCs transplanted into a SCI model in rats, where no differences were reported with regard to graft efficiency, spinal cord tissue sparing, or glial scar reduction [78].

The issue of scaling up potential therapeutics is an area in SCI research that is not well documented but has important implications in the clinical setting when the lesion size in

Table 1. Animal models of SCI and bone marrow stem cell transplantation

Reference	Lesion	Transplant	Donor/recipient species	Histological outcome	Functional outcome
Chopp et al. [19, 21]	Thoracic: 10 g weight-drop device with 2.5-mm impactor head, dropped from a height of 25 mm	2.5×10^5 cultured MSCs were injected directly into the lesion 7 days after SCI	Rat/rat	Transplanted MSCs were distributed throughout the damaged tissue and expressed the neuronal marker, NeuN	Significant improvement on BBB scores
Sasaki et al. [16]	Thoracic: focal demyelinated lesion using x-irradiation and ethidium bromide	1×10^4 mononuclear bone marrow cells or CD34+ bone marrow cells were injected directly into the lesion 3 days after ethidium bromide injection	Mouse/rat	Peripheral pattern of remyelination was observed in transplanted animals	No functional assessments
Akiyama et al. [78]	Thoracic: focal demyelinated lesion using x-irradiation and ethidium bromide	1×10^7 mononuclear bone marrow cells were injected intravenously 3 days after irradiation	Rat/rat	Central and peripheral patterns of remyelination observed in transplanted animals	Increased conduction velocity of remyelinated axons
Akiyama et al. [18]	Thoracic: focal demyelinated lesion using x-irradiation and ethidium bromide	5×10^3 cultured MSCs were injected directly into the lesion 3 days after irradiation	Mouse/rat	Central and peripheral patterns of remyelination observed in transplanted animals	Increased conduction velocity of remyelinated axons
Hofstetter et al. [20]	Thoracic: weight dropped from a height of 25 mm	3×10^5 cultured MSCs were injected directly into the lesion immediately or 7 days after SCI	Rat/rat	Transplanted MSCs formed bridges across the lesion populated by astrocytes and nerve fibers. MSCs expressed NeuN	Significant improvement on BBB scores after delayed MSC transplantation
Wu et al. [21]	Thoracic: 10 g weight-drop device with 2-mm impactor head, dropped from a height of 50 mm	1×10^6 cultured MSCs were injected directly into the lesion immediately after SCI	Rat/rat	Reduced cavity formation	Significant improvement on BBB scores
Ankeny et al. [22]	Thoracic: weight dropped 1 mm in spinal tissue	3×10^5 cultured MSCs were injected directly into the lesion 2 days after SCI	Rat/rat	MSC lesion sites contained increased neurofilament staining and reduced cavity formation	No change on BBB score. Increased spontaneous air-stepping
Ohta et al. [24]	Thoracic: 10 g weight-drop device with 2-mm impactor head, dropped from a height of 12.5 mm (mild) or 25 mm (moderate)	5×10^6 cultured MSCs were injected into the fourth ventricle	Rat/rat	Reduced cavity formation	Significant improvement on BBB scores
Zurita et al. [27]	Thoracic: 25 g weight-drop device with 12-mm ² cylinder, dropped from a height of 20 cm	1×10^6 cultured MSCs were injected directly into the lesion 3 months after SCI	Rat/rat	Transplanted MSCs formed bundles across the lesion and reduced cavity formation. MSCs expressed neurofilament or GFAP	Significant improvement on BBB scores
Lu et al. [49]	Cervical: microwire dorsal column lesion	2×10^5 cultured MSCs, neurally induced MSCs or BDNF-MSCs were injected directly into the lesion immediately after SCI	Rat/rat	Neurons induced from MSCs did not maintain neuronal differentiation but supported axonal regeneration through lesions to the same extent as MSCs, but less than that of BDNF-MSCs	No change on BBB score
Neuhuber et al. [26]	Cervical: 2-mm hemisection	5×10^5 cultured MSCs seeded into gel foam were implanted and $2.5-5 \times 10^5$ MSCs were injected directly into the lesion immediately after SCI	Human/rat	Transplanted MSCs filled the lesion site after 2 weeks, but were absent after 11 weeks. Increased axon growth through SCI sites was donor-dependant	Significant improvement on BBB scores was donor-dependent

TABLE 1. (Continued).

Reference	Lesion	Transplant	Donor/recipient species	Histological outcome	Functional outcome
Sigurjonsson et al. [27]	Lumbar :1–3 segment stretch of neural tube excised	2×10^7 CD34+HSCs were injected directly into the lesion immediately after SCI	Human/embryonic chick	Transplanted HSCs integrated into the spinal cord. HSCs expressed NeuN and possessed axonal and dendritic processes	Transplanted MSCs exhibited indicative neuronal active membrane properties and synaptic potentials
Syková and Jendlová [28]	Thoracic: balloon compression	Cultured MSCs were injected intravenously 7 days after SCI	Rat/rat	Reduced cavity formation	Significant improvement on BBB scores
Čížková et al. [29]	Thoracic: balloon compression	1×10^6 cultured MSCs were injected intravenously 7 days after SCI	Human/rat	Transplanted MSCs had infiltrated the lesion site, some expressed adenomatous polyposis coli (a marker of oligodendroglial cells)	Significant improvement on BBB scores
Himes et al. [30]	Thoracic: 10 g weight dropped from a height of 12.5 mm (mild), 50 mm (severe), or 25 mm (moderate)	5×10^5 cultured MSCs were injected directly into mild/severe lesions, 1×10^6 were injected directly and at the rostral and caudal edge of moderate lesions. All 7 days after SCI	Human/rat	Reduced cavity formation in all groups and increased Schwann cell/oligodendrocyte migration into moderate lesions	Significant improvement on BBB scores in all groups and exploratory rearing and thermal sensitivity in the moderate group
Vaquero et al. [31]	Thoracic: 25 g weight drop device with 12-mm ² cylinder, dropped from a height of 20 cm	3×10^6 cultured MSCs were injected either directly into the lesion or intravenously 3 months after SCI	Rat/rat	Intravenously administered MSCs were shown in 7 of the 20 lesions, MSCs that were injected directly into lesions formed bundles and reduced cavity formation in all rats. These MSCs expressed neurofilament	Significant improvement on BBB scores, this was more pronounced after injection directly into the lesion compared with intravenous delivery
Courtney et al. [79]	Cervical: hemisection	1×10^6 cultured MSCs were injected either via LP or intravenously. In other cases, 4.5×10^5 MSCs were injected directly into the lesion. All immediately after SCI	Human/rat	MSC engraftment was most efficient after direct injection, then via LP and finally via intravenous delivery. Reduced cavity formation and increased tissue sparing in all groups	No functional assessments
Samdani et al. [78]	Cervical: dorsolateral funiculotomy	1.5×10^5 cultured MSCs were injected directly into the lesion immediately after SCI	Human/rat	Reduced cavity formation and increased tissues sparing	No functional assessments

Abbreviations: BBB, ●●●; BDNF, brain-derived neurotrophic factor; GFAP, ●●●; LP, lumbar puncture; MSC, mesenchymal stem cell; SCI, spinal cord injury.

animal models and humans differ greatly. A typical injury in rat models of SCI is 1–3 mm in length into which, generally, $1\text{--}5 \times 10^6$ cells are grafted (summarized in Table 1). In humans, it is perhaps intuitive to consider that more cells may be needed for larger lesions. In addition, if the acute stage of SCI proves a window of opportunity where grafting has beneficial effects then this large cell number must be generated rapidly. Seeding MSCs at low densities significantly reduces the MSC culture doubling time and greatly increased the overall MSC yield [69, 80], which has important implications clinically if MSC number is critical to the success of an MSC graft.

The delivery of HSCs and MSCs into animal CNS injury models varies considerably (Table 1). The method of cell delivery is of great importance to the clinic as injections directly into the spinal cord tissue may cause further damage. However, MSCs exhibit trophism for sites of tissue damage [81] and this may negate the need to inject cells directly into the injury site. Intravenous (IV) applications of MSCs in rodent models of SCI and brain trauma have shown that labeled MSCs can migrate toward and integrate into damaged CNS tissues up to 3 months post-transplantation [82]. MSCs have also been injected directly into the cerebrospinal fluid by lumbar puncture (LP) in animal models of SCI, where they migrated into injured spinal tissue and reduced cyst size and increased functional recovery [24, 79, 83, 84]. A direct comparison between the efficacy of these modes of delivery (IV vs. LP) and their effects on the host has previously been made [79]. In this study, human MSC engraftment into the injured spinal cord tissue in rats was determined as a percentage of total cord volume at 4 and 21 days after MSC delivery. When MSCs were injected intravenously, MSC engraftment was reported at 2.3% and 1.6%, whereas LP delivery increased MSC engraftment to 4.1% and 3.4% after 4 and 21 days, respectively. In addition, the increased engraftment of LP-delivered cells was associated with a decreased host immune response, increased tissue sparing, and decreased glial scarring compared with animal, which were injected intravenously [79]. This study highlights the importance of cell number in determining the outcome of cell transplantation; furthermore, the study represents a promising advance to the clinical use of MSC in SCI treatment as IV and LP colony-stimulating factor (CSF) infusion are minimally invasive delivery techniques.

The majority of HSC and MSC transplantations in animal models of SCI occur in the acute injury phase [19–24, 26–30]. However, there are a number of studies using chronic models of SCI in animals that have reported increased functional recovery following MSC transplantation 6–12 weeks after injuries were induced, which is considered chronic in these model systems [25, 31]. This literature indicates that both the acute, subacute, and chronic injury may well be a therapeutic target for MSC grafting. The acute or subacute milieu of the damaged spinal cord may influence the mechanism by which HSC or MSC graft might induce tissue protection/repair in a manner that differs to the chronic setting (e.g., in the acute setting for anti-inflammatory purposes or in the subacute/chronic setting for neurostimulatory and cell bridging effects and possibly glial or neuronal cell replacement). No physical therapy following HSC or MSC transplantation has been reported in any of the animal models reviewed in this article. It will be important to study these effects in future studies using HSCs and MSCs, as locomotor training activity when combined with other types of cell transplant has previously been reported to improve functional recovery in animal models of SCI [85].

Current Bone Marrow Cell Clinical Trials for the Treatment of SCI

The current bone marrow cell clinical trials for the treatment of SCI are summarized in Table 2. There are no definitive rules for the classification of SCI as acute, subacute, or chronic. In general, provided there are no life-threatening-associated injuries or complications, the acute stage is likely to last up to the end of the period of spinal shock during which the patient is at the highest risk of developing complications. However, the presence of life-threatening-associated injuries or complications can prolong the acute stage until such conditions no longer pose a threat. The subacute stage can be described as the period during which all systems of the body that are affected by the SCI are managed and retrained to function as safely and as conveniently as possible. This usually lasts up to 6 months, occasionally longer. The International Campaign for Cures of SCI Paralysis (ICCP) have stated that “based on the available data, it might be suggested that the chronic state is only attained 12 months after SCI (where the preceding 6 months have indicated no change in functional capacity, thereby providing a stable baseline).” [86]. However, the criteria for acute, subacute, and chronic SCI are disputable and vary greatly among the clinics reviewed in this article. Therefore, we have described each trial according to their respective clinical classification, while also including the actual times of injury onset. In two of these studies, MCPs have been trialed in conjunction with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration. GM-CSF has previously been shown to mobilize MCPs into the injured spinal cord and promote functional recovery from SCI in mice [87]. For these clinical trials, it was hypothesized that GM-CSF would not only promote the migration of MCPs into the lesioned spinal cord but also would have a direct effect on the transplanted cells by enhancing their survival and activating them to secrete neurotrophic cytokines [70, 73]. The first trial used a combination of MCPs with administration of GM-CSF in the acute setting, that is, within 7 days of injury with cells injected directly into the lesion site [70]. Of the six patients who were treated, five showed slightly improved neurological function. This same group of researchers have now gone on to treat a further 17 patients with SCI at 2 weeks postinjury (i.e., still acute), 6 patients between 14 days to 8 weeks postinjury (subacute), and 12 patients at >8 weeks postinjury (chronic) [73]. A control group of 13 patients were also included; these patients were treated only with conventional decompression and fusion surgery. In this latter study, 29.5% of the acute, 33.3% of the subacute, 0% of the chronic, and 7.7% of the control patients demonstrated an increase in neurological function at 10 months post-transplantation. However, as few patients have been treated at this stage, it is not clear whether the neurological improvements noted were directly attributable to the treatment and were not due to an intrinsic repair process and natural recovery.

A preliminary safety study on the use of MCPs delivered via LP also with administration of GM-CSF for the treatment of SCI has been reported [71]. Ten patients with SCI were treated 4 hours after the bone marrow was aspirated and 100 million MCPs were injected. This brief study reported that no serious adverse effects were observed at 12 weeks follow-up, although no detailed neurological assessments were performed [71]. Another trial safely treated 20 patients with SCI ranging from 10 to 467 days postinjury with MCPs injected intra-arterially or by IV within 5 hours of harvesting [72]. The improved neurological outcome reported in one chronic patient who was neurologically stable for several months prior

Table 2. Clinical trials for the treatment of SCI using bone marrow

Reference	Patient group	Transplant	Follow-up
Park et al. [70]	Six patients with complete SCI. ASIA impairment scale A was assessed for this protocol. Five cervical and one thoracic	Acute (7 days after SCI) patients were transplanted with 1.98×10^9 autologous MCPs injected directly into the lesion. After surgery, a total of five cycles (daily for the first 5 days of each month over 5 months) of GM-CSF was injected subcutaneously (250 mg/m^2 of body surface area). No control group was included in this study	Follow-up duration ranged from 6 to 18 months. Five of the six patients showed improved neurological function (one patient improved from ASIA A to B and four improved from ASIA A to C). No serious complications, that is, increased mortality and morbidity or worsening of neurological function were reported. Although GM-CSF administration induced fever, myalgic pain, and leukocytosis
Callera and do Nascimento [71]	Ten patients with SCI were assessed for this protocol	Chronic (mean 3 years after SCI) patients were transplanted with 1.98×10^9 autologous MCPs injected via LP into the CSF. No control group was included in this study	No neurological assessments were reported. No serious complications were reported
Syková et al. [72]	Fifteen patients with complete SCI ASIA A and five with incomplete SCI, four ASIA B and 1 ASIA C were assessed for this protocol. Twelve cervical and eight thoracic	Seven acute/subacute (10–30 days after SCI) and 13 chronic (2–17 months after SCI) patients were transplanted with $10^9 \pm 55.3 \times 10^8$ autologous MCPs injected either intra-arterially ($n = 6$) or intravenously ($n = 14$). No control group was included in this study	Follow-up duration ranged from 3 to 12 months. All four acute/subacute and one of the two chronic patients that received intra-arterial MCP delivery showed improved neurological function. Of the 14 patients who received intravenous MCP transplants only one acute/subacute patient showed an improved ASIA score. No serious complications were reported
Yoon et al. [73]	Forty eight patients with complete SCI. All ASIA A were assessed for this protocol. Thirty cervical and 18 thoracic	Seventeen acute (within 14 days of SCI), six subacute (between 14 days and 8 weeks after SCI) and 12 chronic (more than 8 weeks after SCI) patients were transplanted with 2×10^8 autologous MCPs injected directly into the lesion. After surgery, a total of five cycles (daily for the first 5 days of each month over 5 months) of GM-CSF was injected subcutaneously (250 mg/m^2 of body surface area). Thirteen control patients were treated with conventional decompression and fusion surgery	Mean follow-up duration was 10 months, 29.5% of acute, 33.3% of subacute 0% of chronic, and 7.7% of control patients showed improved neurological function. No serious complications, sepsis, or wound infections were reported. Although GM-CSF administration induced fever, facial rashes/flushing, and headaches. Some patients in both the treatment and control groups also experienced neuropathic pain
Deda et al. [74]	Nine patients with complete SCI. All ASIA A were assessed for this protocol. Six cervical and three thoracic	Chronic (more than 6 months after SCI) patients were transplanted with between 20×10^6 and 67×10^6 autologous MCPs injected at multiple sites directly into the lesion, in a carrier gel foam covering the lesion and intravenously. MCPs had been subjected to one freeze-thaw cycle. No control group was included in this study	Follow-up duration of 1 year. All of the patients showed improved neurological function (1 patient improved from ASIA A to B and eight improved from ASIA A to C). No serious complications were reported
Geffner et al. [75]	Five patients with complete SCI ASIA A and three with incomplete SCI, one ASIA B and two ASIA C were assessed for this protocol. All thoracic	Four acute (5 days to 7 months after SCI) and four chronic (5–21 years after SCI) patients were transplanted with a mean population of 4×10^8 autologous MCPs. Following the removal of glial scar tissue and detethering the spinal cord MCPs were injected at multiple sites directly into the cavity, via LP and intravenously. No control group was included in this study	Follow-up duration of 2 years. Three of the four acute patients showed improved neurological function (ASIA A to C) and 3 of the four chronic patients also improved (one patient improved from ASIA A to C, one from ASIA B to C and one from ASIA C to D). All transplanted patients demonstrated increased bladder control/sensation and had improved quality of life scores. No serious complications were reported
Saito et al. [76]	Case report: one patient with ASIA A, cervical SCI was assessed for this protocol	Acute (13 days after SCI) this patient was transplanted with 3.1×10^7 autologous cultured MSCs via LP. No control group was included in this study	Follow-up duration of 6 months. Motor and sensory scores gradually improved at 1 and 3 months compared with the scores before transplantation. A slight improvement to motor but not sensory score was also observed at 6 months compared with that at 3 months. No serious complications were reported
Pal et al. [77]	Twenty patients with complete SCI. ASIA A and five with complete SCI ASIA C were assessed for this protocol. Three cervical and 22 thoracic	Fifteen acute (<6 months after SCI) and 10 chronic (>6 months after SCI) patients were transplanted with two doses of 1×10^6 autologous cultured MSCs per kilogram of body weight at 1-week interval via LP. No control group was included in this study	Follow-up duration ranged from 1 to 3 years. No significant improvement in neurological ASIA scores were reported. However, patients with less than 6 months of thoracic level injury showed some improvement in quality of life score. No serious complications were reported

Abbreviations: ASIA, All American Spinal Injury Association; CSF, colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; LP, lumbar puncture; MCP, mononuclear cells preparation; SCI, spinal cord injury.

to cell implantation is promising. A case report on SCI treatment via LP delivery of cultured MSCs, where the patient was treated 13 days after SCI, reported that no adverse effects were noted in the 6 months follow-up to the treatment and both motor and sensory neurological scores gradually improved [76]. However, as with previous solely acute studies, these improvements are difficult to separate from an intrinsic repair process. Indeed, in a recent study using LP MSC transplantation for SCI repair in a more extensive cohort of patients, only the acute patient group demonstrated any improvement in quality of life score and patients with chronic injuries failed to show any improvements [77]. In contrast, increased functional recovery and improved quality of life was reported after treating four acute and four patients with chronic SCI with ~800 million MCPs via multiple routes, ~200 million cells were injected directly into the injury site after the removal of glial scar tissue and ~300 million cells were delivered by both LP and IV administration [75]. Similar functional improvements have been reported in nine chronic patients following transplantation directly into the spinal cord tissue with MCPs, which had been subjected to a freeze-thaw cycle, suggesting that cryopreserved MCPs do not lose the ability to promote functional recovery [74]. Therefore, harvested cells could be cryopreserved and stored for future use. The improved neurological outcome reported in these chronic patients is exciting, although a control group was again not included in either study for comparison [74, 75]. Inclusion of a control group is of particular importance for the former study to access the effects of scar removal in the absence of MCP transplantation for comparison.

Larger patient cohorts would be required to determine the significance of any functional improvements in these patient trials and to assess any associated risks of MCP/MS or GM-CSF treatments. It is noteworthy that no details of physical rehabilitation were reported in any of these clinical trials other than that "all patients underwent standard physical therapy prior to and after transplantation" [75]. For future reporting of clinical trials it will be important to include the details of any physical rehabilitation programs, which have previously been demonstrated to impact significantly on SCI recovery [88]. It is currently unclear whether cell transplantation in future SCI treatments should be limited to the acute,

subacute, or chronic phase of injury. Indeed, it is highly likely that all of these stages may be targeted. However, when considering suitable patients to include for clinical trials, chronic patients with a stable neurological function (or dysfunction) would give the clearest indication that any functional improvements following bone marrow cell transplantation were due to that treatment and were not due to natural recovery [89]. To address these issues, the ICCP has published clear guidelines for devising future clinical trials (www.campaignforcurcure.org/iccp) [86]. This in itself is exciting news, which suggests that as a whole, the field of SCI research is an active area close to meaningful clinical translation.

CONCLUSION

The potential of bone marrow cell transplantation as a method of repair in the injured CNS may serve a number of different purposes that span various therapeutic targets. Animal studies have demonstrated that transplanted MSCs modify the inflammatory environment in the acute setting and reduce the effects of the inhibitory scar tissue in the subacute/chronic setting to provide a permissive environment for axonal extension. In addition, grafted cells may provide a source of growth factors to enhance axonal elongation across spinal cord lesions. Other studies have suggested that HSCs and MSCs may even transdifferentiate to replace lost or damaged neuronal tissue. Preliminary clinical data indicates that autologous bone marrow cell transplantation and/or GM-CSF administration can be used to treat patients with SCI without any immediate serious complications. These data are promising, but future studies must continue to establish whether bone marrow cell treatments can serve as a safe and functional autologous source for the treatment of the injured CNS.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

AQ7

REFERENCES

- Ramer MS, Harper GP, Bradbury EJ. Progress in spinal cord research (review). *Spinal Cord* 2000;38:449–472.
- Noble LJ, Donovan F, Igarashi T et al. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vasculature events. *J Neuroscience* 2002;22:7526–7535.
- Taoka Y, Okajima K, Uchiba M et al. Role of neutrophils in spinal cord injury in the rat. *Neuroscience* 1997;74:1177–1182.
- Popovich PG, Guan Z, McGuagh V et al. The neuropathological, behavioural consequences of intraspinal microglial/ macrophage activation. *J Neuropathol Exp Neurol* 2002;61:623–633.
- Carlson SL. Acute inflammatory response in the spinal cord following impact injury. *Exp Neurol* 1999;151:77–88.
- McKerracher L, David S, Jackson DL et al. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite outgrowth. *Neuron* 1994;13:805–811.
- Chen MS, Huber AB, van der Haar ME et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. *Nature* 2000;403:434–439.
- David S, Bouchard C, Tsatas O et al. Macrophages can modify the non-permissive nature of the adult mammalian CNS. *Neuron* 1990;5:463–469.
- Rabchevsky AG, Striet WJ. Role of microglia in post injury repair and regeneration of the CNS. *Ment Retard Dev Disabil Res Rev* 1998;4:187–192.
- Fawcett JW, Asher RA. The glial scar and central nervous system repair (review). *Brain Res Bull* 1999;49:377–391.
- Zuo J, Neubauer D, Dyess K et al. Degradation of chondroitin sulphate proteoglycan enhances the neurite promoting potential of spinal cord tissue. *Exp Neurol* 1998;154:654–666.
- Bradbury RJ, King VR, Bennet GS et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* 2002;416:636–640.
- Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. *Nature* 2001;409:341–346.
- Oertle T, van der Haar ME, Bandtlow CE et al. Nogo-A inhibits neurite outgrowth and cell spreading with three distinct regions. *J Neurosci* 2003;23:5393–5406.
- Wang KC, Koprivica V, Kim JA et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. *Nature* 2002;417:941–944.
- Sasaki M, Honmou O, Akiyama Y et al. Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. *Glia* 2001;35:26–34.
- Akiyama Y, Radtke C, Honmou O et al. Remyelination of the spinal cord following intravenous delivery of bone marrow stromal cells. *Glia* 2002;39:229–236.
- Akiyama Y, Radtke C, Kocsis JD. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. *J Neurosci* 2002;22:6623–6630.
- Chopp M, Zhang XH, Li Y et al. Spinal cord injury in rat: Treatment with bone marrow stromal cell transplantation. *NeuroReport* 2000;11:3001–3005.

AQ8

- 20 Hofstetter CP, Schwarz EJ, Hess D et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. *Proc Natl Acad Sci USA* 2002;99:2199–2204.
- 21 Wu S, Suzuki Y, Ejiri Y et al. Bone marrow stromal cells enhance differentiation of co-cultured neurosphere cells and promote regeneration of the injured spinal cord. *J Neurosci Res* 2003;72:343–351.
- 22 Ankeny DP, McTigue DM, Jakeman LB. Bone marrow transplants provide tissue protection and directional guidance for axons after contusive spinal cord injury in rats. *Exp Neurol* 2004;190:17–31.
- 23 Koshizuka S, Okada S, Okawa A et al. Transplanted hematopoietic stem cells from bone marrow differentiate into neural lineage cells and promote functional recovery after spinal cord injury in mice. *J Neuropathol Exp Neurol* 2004;63:64–72.
- 24 Ohta M, Suzuki Y, Noda T et al. Bone marrow stromal cells infused into the rat cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. *Exp Neurol* 2004;187:266–278.
- 25 Zurita M, Vaquero J. Functional recovery in chronic paraplegia after bone marrow stromal cells transplantation. *Neuroreport* 2004;15:1105–1108.
- 26 Neuhuber B, Himes BT, Shumsky JS et al. Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. *Brain Res* 2005;1035:73–85.
- 27 Sigurjonsson OE, Perreault M-C, Egeland T et al. Adult human hematopoietic stem cells produce neurons efficiently in the regenerating chicken embryo spinal cord. *Proc Natl Acad Sci USA* 2005;102:5227–5232.
- 28 Syková E, Jendlová P. Magnetic resonance tracking of implanted adult and embryonic stem cells in injured brain and spinal cord. *Ann N Y Acad Sci* 2005;1049:146–160.
- 29 Čížková D, Rosocha J, Vanický I et al. Transplantation of human mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. *Cell Mol Neurobiol* 2006;26:1167–1180.
- 30 Himes BT, Neuhuber B, Coleman C et al. Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord. *Neurorehabil Neural Repair* 2006;20:278–296.
- 31 Vaquero J, Zurita M, Oya S et al. Cell therapy using bone marrow stromal cells in chronic paraplegic rats: systemic or local administration? *Neurosci Lett* 2006;398:129–134.
- 32 Weissman IL. Stem cells: Units of development, units of regeneration, and units of evolution (review). *Cell* 2000;100:157–168.
- 33 Wilson A, Trump A. Bone-marrow haematopoietic stem-cell niches (review). *Nat Rev Immunol* 2006;6:93–105.
- 34 Wognum AW, Eaves AC, Thomas TE. Identification and isolation of hematopoietic stem cells (review). *Arch Med Res* 2003;34:461–75.
- 35 Pittenger MF, Mackay A, Beck SC et al. Multilineage potential of adult mesenchymal stem cells. *Science* 1999;284:145–147.
- 36 Dezawa M, Hoshino M, Nabeshima Y et al. Marrow stromal cells: Implications in health and disease in the nervous system (review). *Curr Mol Med* 2005;5:723–732.
- 37 Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–317.
- 38 Krabbe C, Zimmer J, Meyer M. Neural transdifferentiation of mesenchymal stem cells—A critical review. *APMIS* 2005;113:831–844.
- 39 Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system (review). *Curr Pharm Des* 2005;11:1255–1265.
- 40 Chen Y, Teng FY, Tang BL. Coaxing bone marrow stromal mesenchymal stem cells towards neuronal differentiation: Progress and uncertainties (review). *Cell Mol Life Sci* 2006;63:1649–1657.
- 41 Brazzilay R, Melamed E, Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: Making transdifferentiation possible (review). *Stem Cells* 2009;27:2509–2515.
- 42 Lu P, Blesch A, Tuszynski MH. Induction of bone marrow stromal cells to neurons: Differentiation, transdifferentiation or artifact? *J Neurosci Res* 2004;77:174–191.
- 43 Brazzelton TR, Rossi FMV, Keshet GI et al. From marrow to brain: Expression of neuronal phenotypes in adult mice. *Science* 2000;290:1775–1779.
- 44 Mezey E, Chandross KJ, Harta G et al. Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow. *Science* 2000;290:1779–1782.
- 45 Weimann JM, Johansson BC, Trejo A et al. Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. *Nat Cell Biol* 2003;5:959–966.
- 46 Cho KJ, Trzaska KA, Greco SJ et al. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 α . *Stem Cells* 2005;23:383–391.
- 47 Wislet-Gendebien S, Hans G, LePrince P et al. Plasticity of cultured mesenchymal stem cells: Switch from nestin-positive to excitable neuron-like phenotype. *Stem Cells* 2005;23:392–402.
- 48 Keilhoff G, Gohl A, Langnase K et al. Transdifferentiation of mesenchymal stem cells into Schwann cell-like myelinating cells. *Eur J Cell Biol* 2006;85:11–24.
- 49 Lu P, Jones LL, Tuszynski MH. BDNF-expressing marrow stromal cells support extensive axonal growth at sites of spinal cord injury. *Exp Neurol* 2005;191:344–360.
- 50 Takakura N, Watanabe T, Suenobu S et al. A role for hematopoietic stem cells in promoting angiogenesis. *Cell* 2000;102:199–209.
- 51 Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. *Blood* 2002;99:3838–3843.
- 52 Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. *Exp Hematol* 2002;30:42–48.
- 53 Jiang X-X, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte derived dendritic cells. *Blood* 2005;105:4120–4126.
- 54 Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. *Blood* 2006;107:367–372.
- 55 Birdsall Abrams MB, Dominguez C, Pernold K et al. Multipotent mesenchymal stromal cells attenuate chronic inflammation and injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury. *Restor Neurol Neurosci* 2009;27:301–321.
- 56 Trivedi A, Olivas AD, Linda J et al. Inflammation and spinal cord injury: Infiltrating leukocytes as determinants of injury and repair processes. *Clin Neurosci Res* 2006;6:283–292.
- 57 Crigler L, Robey RC, Asawachaicharn A et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neurogenesis. *Exp Neurol* 2006;198:54.
- 58 Wright KT, El Masri WE, Osman A et al. Bone marrow stromal cells stimulate neurite outgrowth over neural proteoglycans (CSPG), myelin associated glycoprotein and Nogo-A. *Biochem Biophys Res Commun* 2007;354:559–566.
- 59 Phinney DG, Baddoo M, Dutriol M et al. Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration. *Stem Cells Dev* 2006;15:437–447.
- 60 Son RR, Marquez-Curtis LA, Kucia M et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. *Stem Cells* 2006;24:1254–1264.
- 61 d'Ortho MP, Will H, Atkinson S et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. *Eur J Biochem* 1997;250:751–757.
- 62 Passi A, Negrini D, Albertini R et al. The sensitivity of versican from rabbit lung to gelatinase A (MMP-2) and B (MMP-9) and its involvement in the development of hydraulic lung edema. *FEBS Lett* 1999;456:93–96.
- 63 Zhukareva V, Obrocka M, Houle JD et al. Secretion profile of human bone marrow stromal cells: Donor variability and response to inflammatory stimuli. *Cytokine* 2010;50:317–321.
- 64 Minaire P, Edouard C, Arlot M et al. Marrow changes in paraplegic patients. *Calcif Tissue Int* 1984;36:338–340.
- 65 Klein-Nulend J, Bacabac RG, Mullender MG. Mechanobiology of bone tissue. *Pathol Biol* 2005;53:576–580.
- 66 Hill EL, Elde R. Effects of neonatal sympathectomy and capsaicin treatment on bone remodelling in rats. *Neurosci* 1991;44:747–755.
- 67 Iversen PO, Hjeltnes N, Holm Blorn et al. Depressed immunity and impaired proliferation of hematopoietic progenitor cells in patients with complete spinal cord injury. *Hematopoiesis* 2000;96:2081–2083.
- 68 Chernykh ER, Shevela EY, Leplina OY et al. Characteristics of bone marrow cells under conditions of impaired innervation in patients with spinal trauma. *Bull Exp Biol Med* 2006;141:117–120.
- 69 Wright KT, El Masri WE, Osman A et al. The cell culture expansion of bone marrow stromal cells from humans with spinal cord injury: Implications for future cell transplantation therapy. *Spinal Cord* 2008;46:811–817.
- 70 Park HS, Park HC, Shim YS et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. *Tissue Eng* 2005;11:913–922.
- 71 Callera F, do Nascimento. Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: A preliminary safety study. *Exp Hematol* 2006;34:130–131.

AQ9

- 72 Syková E, Homola A, Mazanec R et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. *Cell Transplant* 2006;15:675–687.
- 73 Yoon SH, Shim YS, Park YH et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase I/II clinical trial. *Stem Cells* 2007;25:2066–2073.
- 74 Deda H, Inci MC, Kurekci AE et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. *Cytotherapy* 2008;10:565–574.
- 75 Geffner LF, Santacruz P, Izurieta M et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. *Cell Transplant* 2008;17:1277–1293.
- 76 Saito F, Nakatani T, Iwase M et al. Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: The first clinical trial case report. *J Trauma* 2008;64:53–59.
- 77 Pal R, Venkatamana NK, Bansal A et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/ paraplegia: A pilot clinical study. *Cytotherapy* 2009;11: 897–911.
- 78 Samdani AF, Paul C, Betz RR et al. Transplantation of human marrow stromal cells and mono-nuclear bone marrow cells into the injured spinal cord. *Spine* 2009;34:2605–2612.
- 79 Courtney P, Samdani AF, Betz RR et al. Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods. *Spine* 2009;34:328–334.
- 80 Neuhuber B, Swagner SA, Howard L et al. Effects of plating density and culture time on bone marrow stromal cell characteristics. *Exp Hematol* 2008;36:1176–1185.
- 81 Spaeth E, Klopp A, Dembinski J et al. Inflammation and tumour microenvironments: Defining the migratory itinerary of mesenchymal stem cells. *Gene Ther* 2008;15:730–738.
- 82 Corti S, Locatelli F, Donadoni C et al. Neuroectodermal and microglial differentiation of bone marrow cells in the mouse spinal cord and sensory ganglia. *J Neuroscience Res* 2002;70:721–733.
- 83 Satake K, Lou J, Lenke LG. Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. *Spine* 2004;29:1971–1979.
- 84 Bakshi A, Barshinger AL, Swanger SA et al. Lumbar puncture delivery of bone marrow stromal cells in spinal cord contusion: A novel method for minimally invasive cell transplantation. *J Neurotrauma* 2006;23:55–65.
- 85 Nothias JM, Mitsui T, Shumsky JS et al. Combined effects of neurotrophin secreting transplants, exercise, and serotonergic drug challenge improve function in spinal rats. *Neurorehabil Neural Repair* 2005;19: 296–312.
- 86 Fawcett JW, Curt A, Steeves JD et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel. *Spinal Cord* 2007;45:190–242.
- 87 Koda M, Nishio Y, Kamada T et al. Granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into injured spinal cord and promotes functional recovery after compression-induced spinal cord injury in mice. *Brain Res* 2007;1149:223–231.
- 88 Mehrholz J, Kugler J, Pohl M. Locomotor training for walking after spinal cord injury. *Spine* 2008;33:768–777.
- 89 Katoh S, El Masri W. Neurological recovery after conservative treatment of cervical cord injuries. *J Bone Joint Surg Br* 1994;76B:225–228.
- 90 Kondo M, Wagers AJ, Manz MG et al. Biology of hematopoietic stem cells and progenitors: Implications for clinical application (review). *Annu Rev Immunol* 2003;21:759–806.



See www.StemCells.com for supporting information available online.

Author Proof

AQ1: Kindly check whether the affiliations are linked to appropriate author names.

AQ2: Kindly check whether the third affiliation is OK as typeset.

AQ3: Per journal style, most nonstandard abbreviations must be used at least two times in the abstract to be retained; CNS was used once and has thus been deleted.

AQ4: Per journal style, most nonstandard abbreviations must be used at least two times in the text to be retained; bFGF was used once and has thus been deleted.

AQ5: Please note that Ref. 90 (originally numbered [35]) was not cited anywhere in the text and has therefore been kept at the end. Can this be deleted? If it needs to be inserted anywhere in the text, kindly renumber all citations and references accordingly.

AQ6: Kindly spell out HLA-DR in the text.

AQ7: Kindly check whether the potential conflict of interest information is OK as typeset.

AQ8: Kindly check whether the journal title is OK as typeset for Ref. 9.

AQ9: Kindly provide the complete page range for Ref. 57.

AQ10: Kindly check whether the author name is OK as typeset for Ref. 77.

AQ11: Please supply all degrees (such as M.D. or Ph.D.) held by corresponding author in correspondence line per journal style. Please provide any author contact information (Fax number) that was not supplied to the editorial office at the time of submission.

AQ12: Please note that the year in references mentioned in tables have been deleted. Kindly check for the appropriateness of the author names and respective reference citations in the Tables 1 and 2.

AQ13: Please note that the author name “Chopp et al.” does not match with the Ref. 21 in Table 1. Kindly correct the Table citation or the reference in the list, whichever is incorrect.

AQ14: The name “Akiyama et al.” and “Zurita et al.” mentioned in Table 1 does not match with author names given for Refs. 78 and 27, respectively. Kindly correct the Table citations or the references in the list, whichever is incorrect.

AQ15: Kindly spell out BBB and GFAP in Table 1 footnote.